1
|
Lengacher R, Alberto R. Bioorganometallics: 99mTc cytectrenes, syntheses and applications in nuclear medicine. Coord Chem Rev 2021. [DOI: 10.1016/j.ccr.2021.213869] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
2
|
Exploring the synthesis and characterization of fac-Re(CO)3L complexes using diethylenetriamine derivative functionalized at the central nitrogen. Inorganica Chim Acta 2021. [DOI: 10.1016/j.ica.2021.120291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
3
|
Hao G, Mastren T, Silvers W, Hassan G, Öz OK, Sun X. Copper-67 radioimmunotheranostics for simultaneous immunotherapy and immuno-SPECT. Sci Rep 2021; 11:3622. [PMID: 33574346 PMCID: PMC7878802 DOI: 10.1038/s41598-021-82812-1] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2020] [Accepted: 01/22/2021] [Indexed: 02/01/2023] Open
Abstract
Copper-67 (t1/2 = 2.58 days) decays by β- ([Formula: see text]: 562 keV) and γ-rays (93 keV and 185 keV) rendering it with potential for both radionuclide therapy and single-photon emission computed tomography (SPECT) imaging. Prompted by the recent breakthrough of 67Cu production with high specific activity, high radionuclidic purity, and sufficient quantities, the interest in the theranostic potential of 67Cu has been rekindled. This work addresses the practicability of developing 67Cu-labeled antibodies with substantially improved quality for cancer radioimmunotheranostics. Proof of concept is demonstrated with pertuzumab, a US-FDA-approved monoclonal antibody for combination therapies of HER2-positive breast cancer. With an average number of 1.9 chelators coupled to each antibody, we achieved a two-order of magnitude increase in radiolabeling efficiency compared to literature reports. In a preclinical therapeutic study, mice (n = 4-7/group) bearing HER2+ xenografts exhibited a 67Cu-dose dependent tumor-growth inhibition from 67Cu-labeled-Pertuzumab co-administered with trastuzumab. Furthermore, greater tumor size reduction was observed with 67Cu-labeled-pertuzumab formulations of higher specific activity. The potential of SPECT imaging with 67Cu radiopharmaceuticals was tested after 67Cu-labeled-Pertuzumab administration. Impressively, all tumors were clearly visualized by SPECT imaging with 67Cu-labeled-Pertuzumab even at day 5 post injection. This work demonstrates it is practical to use 67Cu radioimmunoconjugates for cancer radioimmunotheranostics.
Collapse
Affiliation(s)
- Guiyang Hao
- Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA
| | - Tara Mastren
- Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA
| | - William Silvers
- Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA
| | - Gedaa Hassan
- Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA
| | - Orhan K Öz
- Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA
| | - Xiankai Sun
- Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
- Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
| |
Collapse
|
4
|
Lewis MR, Cutler CS, Jurisson SS. Targeted Antibodies and Peptides. Mol Imaging 2021. [DOI: 10.1016/b978-0-12-816386-3.00022-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
5
|
Leyva E, Platz MS, Loredo-Carrillo SE, Aguilar J. Fluoro Aryl Azides: Synthesis, Reactions and Applications. CURR ORG CHEM 2020. [DOI: 10.2174/1385272824999200608132505] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background:
The complex photochemistry of aryl azides has fascinated scientists
for several decades. Spectroscopists have investigated the intermediates formed by
different analytical techniques. Theoretical chemists have explained the intrinsic interplay of
intermediates under different experimental conditions.
Objective & Method:
A complete understanding of the photochemistry of a given fluoro
aryl azide is a basic requisite for its use in chemistry. In this review, we will discuss the
synthesis of several fluoro substituted aryl azides and the reactions and intermediates generated
upon photolysis and thermolysis of these azides and some examples of their applications
in photoaffinity labeling and organic synthesis.
Conclusion:
In spite of the extensive research on the photochemistry of fluoro aryl azides, there are some areas
that remain to be investigated. The application of this reaction in the synthesis of novel heterocyclic compounds
has not been fully studied. Since fluorophenyl azides are known to undergo C-H and N-H insertion reactions,
they could be used to prepare new fluorinated molecules or in the biochemical process known as photoaffinity
labeling.
Collapse
Affiliation(s)
- Elisa Leyva
- Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Manuel Nava No. 6, San Luis Potosí, S.L.P., 78210, Mexico
| | - Matthew S. Platz
- Department of Chemistry, University of Hawaii, Hilo, 200 West Kawili St. Hilo, HI 96720, United States
| | - Silvia E. Loredo-Carrillo
- Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Manuel Nava No. 6, San Luis Potosí, S.L.P., 78210, Mexico
| | - Johana Aguilar
- Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Manuel Nava No. 6, San Luis Potosí, S.L.P., 78210, Mexico
| |
Collapse
|
6
|
Souliotis GA, Rodrigues MRD, Wang K, Iacob VE, Nica N, Roeder B, Tabacaru G, Yu M, Zanotti-Fregonara P, Bonasera A. A novel approach to medical radioisotope production using inverse kinematics: A successful production test of the theranostic radionuclide 67Cu. Appl Radiat Isot 2019; 149:89-95. [PMID: 31035108 DOI: 10.1016/j.apradiso.2019.04.019] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2019] [Revised: 03/31/2019] [Accepted: 04/16/2019] [Indexed: 11/28/2022]
Abstract
A novel method for the production of important medical radioisotopes has been developed. The approach is based on performing the nuclear reaction in inverse kinematics, namely sending a heavy-ion beam of appropriate energy on a light target (e.g. H, d, He) and collecting the isotope of interest. In this work, as a proof-of-concept, we studied the production of the theranostic radionuclide 67Cu (T1/2 = 62 h) via the reaction of a 70Zn beam at 15 MeV/nucleon with a hydrogen gas target. The 67Cu radionuclide alongside other coproduced isotopes, was collected after the gas target on an aluminum catcher foil and their radioactivity was measured by off-line γ-ray analysis. After 36 h post irradiation, apart from the product of interest 67Cu, the main radioimpurity coming from the 70Zn + p reaction was 69mZn (T1/2 = 13.8 h), which can be reduced by further radio-cooling. Moreover, along with the radionuclide of interest produced in inverse kinematics, the production of additional radioisotopes is possible by making use of the forward-focused neutrons from the reaction and allowing them to interact with a secondary target. A preliminary successful test of this concept was realized in the present study. The main requirement to obtain activities appropriate for preclinical studies is the development of high-intensity heavy-ion primary beams.
Collapse
Affiliation(s)
- G A Souliotis
- Laboratory of Physical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Athens, 15771, Greece.
| | - M R D Rodrigues
- Cyclotron Institute, Texas A&M University, College Station, TX, 77843, USA; Instituto de Física, Universidade de São Paulo, São Paulo, 05508-090, Brazil
| | - K Wang
- Cyclotron Institute, Texas A&M University, College Station, TX, 77843, USA
| | - V E Iacob
- Cyclotron Institute, Texas A&M University, College Station, TX, 77843, USA
| | - N Nica
- Cyclotron Institute, Texas A&M University, College Station, TX, 77843, USA
| | - B Roeder
- Cyclotron Institute, Texas A&M University, College Station, TX, 77843, USA
| | - G Tabacaru
- Cyclotron Institute, Texas A&M University, College Station, TX, 77843, USA
| | - M Yu
- Houston Methodist Research Institute, Houston, TX, 77030, USA
| | | | - A Bonasera
- Cyclotron Institute, Texas A&M University, College Station, TX, 77843, USA; Laboratori Nazionali del Sud, INFN, Catania, 95123, Italy
| |
Collapse
|
7
|
Zhang C, Lin KS, Bénard F. Molecular Imaging and Radionuclide Therapy of Melanoma Targeting the Melanocortin 1 Receptor. Mol Imaging 2018; 16:1536012117737919. [PMID: 29182034 PMCID: PMC5714078 DOI: 10.1177/1536012117737919] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Melanoma is a deadly disease at late metastatic stage, and early diagnosis and accurate staging remain the key aspects for managing melanoma. The melanocortin 1 receptor (MC1 R) is overexpressed in primary and metastatic melanomas, and its endogenous ligand, the α-melanocyte-stimulating hormone (αMSH), has been extensively studied for the development of MC1 R-targeted molecular imaging and therapy of melanoma. Natural αMSH is not well suited for this purpose due to low stability in vivo. Unnatural amino acid substitutions substantially stabilized the peptide, while cyclization via lactam bridge and metal coordination further improved binding affinity and stability. In this study, we summarized the development and the in vitro and in vivo characteristics of the radiolabeled αMSH analogues, including 99mTc-, 111In-, 67 Ga-, or 125I-labeled αMSH analogues for imaging with single-photon emission computed tomography; 68Ga-, 64Cu-, or 18F-labeled αMSH analogues for imaging with positron emission tomography; and 188Re-, 177Lu-, 90Y-, or 212Pb-labeled αMSH analogues for radionuclide therapy. These radiolabeled αMSH analogues showed promising results with high tumor uptake and rapid normal tissue activity clearance in the preclinical model of B16F1 and B16F10 mouse melanomas. These results highlight the potential of using radiolabeled αMSH analogues in clinical applications for molecular imaging and radionuclide therapy of melanoma.
Collapse
Affiliation(s)
- Chengcheng Zhang
- 1 Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada
| | - Kuo-Shyan Lin
- 1 Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.,2 Department of Radiology, University of British Columbia, Vancouver, British Columbia, Canada
| | - François Bénard
- 1 Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia, Canada.,2 Department of Radiology, University of British Columbia, Vancouver, British Columbia, Canada
| |
Collapse
|
8
|
Saha P, Naskar JP, Majumder S, Saha B, Ganguly R, Bhattacharya A, Chowdhury S. Experimental and computational studies on a new mixed ligand oxido
-rhenium(V) compound. J CHIN CHEM SOC-TAIP 2018. [DOI: 10.1002/jccs.201800033] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Pinki Saha
- Department of Chemistry; Tripura University; Tripura India
| | - Jnan Prakash Naskar
- Department of Chemistry, Inorganic Chemistry Section; Jadavpur University; Kolkata India
| | - Smita Majumder
- Department of Chemistry; Tripura University; Tripura India
| | - Baptu Saha
- Department of Chemistry; Tripura University; Tripura India
| | - Rakesh Ganguly
- Division of Chemistry & Biological Chemistry; Nanyang Technological University; Singapore Singapore
| | | | - Shubhamoy Chowdhury
- Department of Chemistry; Tripura University; Tripura India
- Department of Chemistry; University of GourBanga; Malda India
| |
Collapse
|
9
|
Application of capillary electrophoresis to the separation of rhenium complex of 1,2,3-trihydroxybenzene. MONATSHEFTE FUR CHEMIE 2017. [DOI: 10.1007/s00706-017-1982-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
10
|
Hosseini SF, Aboudzadeh M, Sadeghi M, Ahmadi Teymourlouy A, Rostampour M. Assessment and estimation of 67Cu production yield via deuteron induced reactions on natZn and 70Zn. Appl Radiat Isot 2017; 127:137-141. [PMID: 28599227 DOI: 10.1016/j.apradiso.2017.05.024] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2017] [Revised: 05/21/2017] [Accepted: 05/30/2017] [Indexed: 02/03/2023]
Abstract
67Cu radioisotope is a beta particle-emitting nuclide used in radioimmunotherapy (RIT) as well as for imaging, tracer kinetic studies and dosimetry. 67Cu can be produced by bombarding natZn with deuterons. In this study, the physical yields of 67Cu via natZn(d,x)67Cu reaction channel as well as via subreactions of 68Zn(d,2pn)67Cu, 67Zn(d,2p)67Cu, 70Zn(d,2p3n)67Cu, 68Zn(d,x)67Ni(T1/2=21s)→67Cu and 70Zn(d,x)67Ni(T1/2=21s)→67Cu in the natZn target have been calculated by using the MCNPX-2.6, TALYS-1.8 and SRIM codes. Also, the total cross sections for production of 67Cu from natZn(d,x)67Cu reaction channel in the energy range of 15-45MeV have been estimated by TALYS code. The best reaction to produce 67Cu radionuclide in a carrier free form was chosen with deuteron energy around 30MeV on 70Zn thick target. Good agreement between the calculated results and the experimental values shows that the employed methods can be used for prediction and production estimation in cyclotron.
Collapse
Affiliation(s)
| | - Mohammadreza Aboudzadeh
- Radiation Application Research School, Nuclear Science and Technology Research Institute, P.O. Box: 11365-8486, Tehran, Iran
| | - Mahdi Sadeghi
- Medical Physics Department, School of Medicine, Iran University of Medical Sciences, P.O. Box: 14155-6183, Tehran, Iran.
| | - Ahmad Ahmadi Teymourlouy
- School of Pharmacy, International Campus, Iran University of Medical Sciences, P.O. Box: 14155-6183, Tehran, Iran
| | | |
Collapse
|
11
|
Govindan SV, Griffiths GL, Hansen HJ, Horak ID, Goldenberg DM. Cancer Therapy with Radiolabeled and Drug/Toxin-conjugated Antibodies. Technol Cancer Res Treat 2016; 4:375-91. [PMID: 16029057 DOI: 10.1177/153303460500400406] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Radioimmunotherapy and antibody-directed chemotherapy have emerged as cancer treatment modalities with the regulatory approval of products for non-Hodgkin's lymphoma and acute myeloid leukemia. Antibody-toxin therapy is likewise on the verge of clinical fruition. Accumulating evidence suggests that radioimmunotherapy may have the best impact in minimal-disease and adjuvant settings, especially with radioresistant solid tumors. For the latter, ongoing efforts in ‘pretargeting’ to increase deliverable tumor radiation dose, combination therapies, and locoregional applications are also of importance. Antibody-drug conjugates have the potential to increase the therapeutic index of chemotherapy by minimizing systemic toxicity and improving tumor targeting. The design of optimal drug conjugates in this regard is predicated upon the proper choice of the target antigen, the cleavable-linker, and the drug. In respect of antibody-toxin conjugates, considerable progress has been made in chemical and recombinant immunotoxin designs, and in the advancement of many products to clinical trials. Continued development of antibody-directed therapies should expand the options available for the management of cancer.
Collapse
|
12
|
Shegani A, Triantis C, Kiritsis C, Raptopoulou C, Psycharis V, Pelecanou M, Pirmettis I, Papadopoulos M. Neutral fac -[Re(NNN)(CO) 3 ] complexes with NNN tridentate ligands containing pyrrole or indole. INORG CHEM COMMUN 2016. [DOI: 10.1016/j.inoche.2015.11.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
13
|
Lim JC, Cho EH, Kim JJ, Choi SM, Lee SY, Nam SS, Park UJ, Park SH. Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting. Nucl Med Biol 2014; 42:234-41. [PMID: 25498002 DOI: 10.1016/j.nucmedbio.2014.10.008] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2014] [Revised: 10/14/2014] [Accepted: 10/15/2014] [Indexed: 10/24/2022]
Abstract
UNLABELLED The gastrin-releasing peptide receptor (GRPR) has been shown to be overexpressed in many human tumors, including prostate, colon, gastric, breast, pancreatic, and small cell lung cancers. Because bombesin (BBS) binds to GRPR with high affinity, BBS derivatives have been labeled with various radionuclides and have been demonstrated to be successful candidates for peptide receptor radiotherapy (PRRT). The present study describes the in vitro and in vivo preclinical characteristics of (177)Lu-DOTA-Lys(glucose)-4 aminobenzoic acid-BBS7-14 ((177)Lu-DOTA-gluBBN) to prepare radiolabeled candidates for the treatment of GRPR-expressing prostate tumors. METHODS (177)Lu-DOTA-gluBBN was prepared as previously published [1]. Human prostate PC-3 tumor cells were used to determine the binding (Kd) retention and efflux of (177)Lu-DOTA-gluBBN. Pharmacokinetic, imaging, and radiotherapy studies were performed in PC-3 xenografted mice. RESULTS The Kd value of (177)Lu-DOTA-gluBBN was 0.63 nM, with a maximum binding capacity (Bmax) of 669.7 fmol/10(6) cells (4.04×10(5) GRPR/cell). During a 2-hr incubation, 90.1±0.4% of the cell-associated radio-peptide was internalized, and 56.3±7.1% of the internalized radio-peptide was externalized in vitro. High amounts of the radio-peptide were rapidly accumulated in a PC-3 tumor in vivo, and the % ID/g of the tumor was 12.42±2.15 1 hr p.i. The radio-peptide was quickly cleared from the blood, yielding tumor-to-blood ratios of 39.22±17.36 at 1 hr p.i. and 330.67±131.23 at 24hr p.i. In addition, (177)Lu-DOTA-gluBBN was clearly visualized in PC-3 tumors 1 hr p.i. and significantly inhibited the tumor growth (P<0.05). Treatment-related toxicity in the pancreas and kidneys was not observed, except for slight glomerulopathy. CONCLUSIONS The pharmacokinetic, imaging, and therapy studies suggest that this (177)Lu-DOTA-gluBBN has promising characteristics for application in nuclear medicine, namely, for the diagnosis and treatment of GRPR-overexpressing prostate tumors.
Collapse
Affiliation(s)
- Jae Cheong Lim
- Radioisotope Research Division, Department of Research Reactor Utilization, Korea Atomic Energy Research Institute, Daejeon 305-353, Republic of Korea; Bio-therapy Human Resources Center, Department of Veterinary Physiology, College of Veterinary Medicine, Chonnam National University, Gwangju 500-757, Korea.
| | - Eun Ha Cho
- Radioisotope Research Division, Department of Research Reactor Utilization, Korea Atomic Energy Research Institute, Daejeon 305-353, Republic of Korea
| | - Jin Joo Kim
- Radioisotope Research Division, Department of Research Reactor Utilization, Korea Atomic Energy Research Institute, Daejeon 305-353, Republic of Korea
| | - Sang Mu Choi
- Radioisotope Research Division, Department of Research Reactor Utilization, Korea Atomic Energy Research Institute, Daejeon 305-353, Republic of Korea
| | - So Young Lee
- Radioisotope Research Division, Department of Research Reactor Utilization, Korea Atomic Energy Research Institute, Daejeon 305-353, Republic of Korea
| | - Sung Soo Nam
- Radioisotope Research Division, Department of Research Reactor Utilization, Korea Atomic Energy Research Institute, Daejeon 305-353, Republic of Korea
| | - Ul Jae Park
- Radioisotope Research Division, Department of Research Reactor Utilization, Korea Atomic Energy Research Institute, Daejeon 305-353, Republic of Korea
| | - Soo Hyun Park
- Bio-therapy Human Resources Center, Department of Veterinary Physiology, College of Veterinary Medicine, Chonnam National University, Gwangju 500-757, Korea.
| |
Collapse
|
14
|
Abhayawardhana PL, Marzilli PA, Fronczek FR, Marzilli LG. Complexes possessing rare "tertiary" sulfonamide nitrogen-to-metal bonds of normal length: fac-[Re(CO)3(N(SO2R)dien)]PF6 complexes with hydrophilic sulfonamide ligands. Inorg Chem 2014; 53:1144-55. [PMID: 24400928 PMCID: PMC4465231 DOI: 10.1021/ic4026987] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Tertiary sulfonamide nitrogen-to-metal bonds of normal length are very rare. We recently discovered such a bond in one class of fac-[Re(CO)3(N(SO2R)(CH2Z)2)](n) complexes (Z = 2-pyridyl) with N(SO2R)dpa ligands derived from di-(2-picolyl)amine (N(H)dpa). fac-[M(CO)3(N(SO2R)(CH2Z)2)](n) agents (M = (186/188)Re, (99m)Tc) could find use as radiopharmaceutical bioconjugates when R is a targeting moiety. However, the planar, electron-withdrawing 2-pyridyl groups of N(SO2R)dpa destabilize the ligand to base and create relatively rigid chelate rings, raising the possibility that the rare M-N(sulfonamide) bond is an artifact of a restricted geometry. Also, the hydrophobic 2-pyridyl groups could cause undesirable accumulation in the liver, limiting future use in radiopharmaceuticals. Our goal is to identify a robust, hydrophilic, and flexible N(CH2Z)2 chelate framework. New C2-symmetric ligands, N(SO2R)(CH2Z)2 with (Z = CH2NH2; R = Me, dmb, or tol), were prepared by treating N(H)dien(Boc)2, a protected diethylenetriamine (N(H)dien) derivative, with methanesulfonyl chloride (MeSO2Cl), 3,5-dimethylbenzenesulfonyl chloride (dmbSO2Cl), and 4-methylbenzenesulfonyl chloride (tolSO2Cl). Treatment of fac-[Re(CO)3(H2O)3](+) with these ligands, designated as N(SO2R)dien, afforded new fac-[Re(CO)3(N(SO2R)dien)]PF6 complexes. Comparing the fac-[Re(CO)3(N(SO2Me)dien)]PF6 and fac-[Re(CO)3(N(SO2Me)dpa)]PF6 complexes, we find that the Re(I)-N(sulfonamide) bonds are normal in length and statistically identical and that the methyl (13)C NMR signal has an unusually upfield shift compared to that in the free ligand. We attribute this unusual upfield shift to the fact that the sulfonamide N undergoes an sp(2)-to-sp(3) rehybridization upon coordination to Re(I) in both complexes. Thus, the sulfonamide N of N(SO2R)dien ligands is a good donor, even though the chelate rings are conformationally flexible. Addition of the strongly basic and potentially monodentate ligand, 4-dimethylaminopyridine, did not affect the fac-[Re(CO)3(N(SO2tol)dien)]PF6 complex, even after several weeks. This complex is also stable to heat in aqueous solution. These results indicate that N(SO2R)dien ligands form fac-[Re(CO)3(N(SO2R)dien)]PF6 complexes sufficiently robust to be utilized for radiopharmaceutical development.
Collapse
Affiliation(s)
| | - Patricia A. Marzilli
- Department of Chemistry, Louisiana State University, Baton Rouge, Louisiana 70803, United States
| | - Frank R. Fronczek
- Department of Chemistry, Louisiana State University, Baton Rouge, Louisiana 70803, United States
| | - Luigi G. Marzilli
- Department of Chemistry, Louisiana State University, Baton Rouge, Louisiana 70803, United States
| |
Collapse
|
15
|
Piotrowska A, Leszczuk E, Bruchertseifer F, Morgenstern A, Bilewicz A. Functionalized NaA nanozeolites labeled with 224,225Ra for targeted alpha therapy. JOURNAL OF NANOPARTICLE RESEARCH : AN INTERDISCIPLINARY FORUM FOR NANOSCALE SCIENCE AND TECHNOLOGY 2013; 15:2082. [PMID: 24307862 PMCID: PMC3840288 DOI: 10.1007/s11051-013-2082-7] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/30/2013] [Accepted: 10/16/2013] [Indexed: 06/01/2023]
Abstract
The 223Ra, 224Ra, and 225Ra radioisotopes exhibit very attractive nuclear properties for application in radionuclide therapy. Unfortunately the lack of appropriate bifunctional ligand for radium is the reason why these radionuclides have not found application in receptor-targeted therapy. In the present work, the potential usefulness of the NaA nanozeolite as a carrier for radium radionuclides has been studied. 224Ra and 225Ra, α-particle emitting radionuclides, have been absorbed in the nanometer-sized NaA zeolite (30-70 nm) through simple ion exchange. 224,225Ra-nanozeolites exhibited very high stability in solutions containing physiological salt, EDTA, amino acids, and human serum. To make NaA nanozeolite particles dispersed in water their surface was modified with a silane coupling agent containing poly(ethylene glycol) molecules. This functionalization approach let us covalently attach a biomolecule to the NaA nanozeolite surface.
Collapse
Affiliation(s)
- Agata Piotrowska
- Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland
| | - Edyta Leszczuk
- Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland
| | - Frank Bruchertseifer
- Institute for Transuranium Elements, Joint Research Centre – European Commission, 76125 Karlsruhe, Germany
| | - Alfred Morgenstern
- Institute for Transuranium Elements, Joint Research Centre – European Commission, 76125 Karlsruhe, Germany
| | - Aleksander Bilewicz
- Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland
| |
Collapse
|
16
|
Beyer T, Hacker M, Schubiger A, Virgolini I, Wester HJ. Nuclear medicine 2013: from status quo to status go. Eur J Nucl Med Mol Imaging 2013; 40:1794-6. [DOI: 10.1007/s00259-013-2570-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2013] [Accepted: 08/30/2013] [Indexed: 01/05/2023]
|
17
|
Comba P, Hunoldt S, Morgen M, Pietzsch J, Stephan H, Wadepohl H. Optimization of Pentadentate Bispidines as Bifunctional Chelators for 64Cu Positron Emission Tomography (PET). Inorg Chem 2013; 52:8131-43. [DOI: 10.1021/ic4008685] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Peter Comba
- Anorganisch-Chemisches Institut, Universität Heidelberg, INF 270, D-69120 Heidelberg, Germany
| | - Sebastian Hunoldt
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, D-01314 Dresden, Germany
| | - Michael Morgen
- Anorganisch-Chemisches Institut, Universität Heidelberg, INF 270, D-69120 Heidelberg, Germany
| | - Jens Pietzsch
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, D-01314 Dresden, Germany
- Department of Chemistry and Food Chemistry, University of Technology Dresden, D-01062 Dresden, Germany
| | - Holger Stephan
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, D-01314 Dresden, Germany
| | - Hubert Wadepohl
- Anorganisch-Chemisches Institut, Universität Heidelberg, INF 270, D-69120 Heidelberg, Germany
| |
Collapse
|
18
|
Taylor SR, Roberts MP, Wyatt NA, Pham TQ, Stark D, Bourdier T, Roselt P, Katsifis A, Greguric I. Synthesis and Radiosynthesis of a Novel PET Fluorobenzyl Piperazine for Melanoma Tumour Imaging; [18F]MEL054. Aust J Chem 2013. [DOI: 10.1071/ch12489] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
2-{2-[4-(4-[18F]-Fluorobenzyl)piperazin-1-yl]-2-oxoethyl}isoindolin-1-one ([18F]MEL054), is a new potent indolinone-based melanin binder designed to target melanotic tumours. [18F]MEL054 was prepared by an automated two-step radiosynthesis, comprising of the preparation of 4-[18F]fluorobenzaldehyde from 4-formyl-N,N,N-trimethylanilinium triflate, followed by reductive alkylation with 2-(2-oxo-2-piperazin-1-ylethyl)isoindolin-1-one. 4-[18F]Fluorobenzaldehyde was prepared on a GE TRACERlab FXFN module in 68 ± 8 % radiochemical yield (RCY, non-decay corrected), purified by a Sep-Pak Plus C18 cartridge and eluted into the reactor of an in-house modified Nuclear Interface [18F]FDG synthesis module for the subsequent reductive alkylation reaction. HPLC purification produced [18F]MEL054 in a collected RCY of 34 ± 9 % (non-decay corrected), the total preparation time (including Sep-Pak Plus C18 and HPLC purification) did not exceed 105 min. The radiochemical purity of [18F]MEL054 was greater than 99 % with a specific radioactivity of 71–119 GBq μmol–1 and [18F]MEL054 remained stable in saline solution (>98 %) after 3 h.
Collapse
|
19
|
Sulieman S, Can D, Mertens J, N’Dongo HWP, Liu Y, Schmutz P, Bauwens M, Spingler B, Alberto R. Cyclopentadienyl-Based Amino Acids (Cp-aa) As Phenylalanine Analogues for Tumor Targeting: Syntheses and Biological Properties of [(Cp-aa)M(CO)3](M = Mn, Re, 99mTc). Organometallics 2012. [DOI: 10.1021/om300695k] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Samer Sulieman
- Institute of Inorganic Chemistry, University of Zürich, Winterthurerstraße
190, CH-8057 Zürich, Switzerland
| | - Daniel Can
- Institute of Inorganic Chemistry, University of Zürich, Winterthurerstraße
190, CH-8057 Zürich, Switzerland
| | - John Mertens
- Radiopharmaceutical Chemistry, Vrije Universiteit Brussel, Laarbeeklaan103, 1090 Brussel,
Belgium
| | - Harmel W. Peindy N’Dongo
- Institute of Inorganic Chemistry, University of Zürich, Winterthurerstraße
190, CH-8057 Zürich, Switzerland
| | - Yu Liu
- Institute of Inorganic Chemistry, University of Zürich, Winterthurerstraße
190, CH-8057 Zürich, Switzerland
| | - Paul Schmutz
- Institute of Inorganic Chemistry, University of Zürich, Winterthurerstraße
190, CH-8057 Zürich, Switzerland
| | - Matthias Bauwens
- Nuclear Medicine,
NUTRIM, Maastricht University, P. Debeyelaan
25, 6229 HX Maastricht,
The Netherlands
| | - Bernhard Spingler
- Institute of Inorganic Chemistry, University of Zürich, Winterthurerstraße
190, CH-8057 Zürich, Switzerland
| | - Roger Alberto
- Institute of Inorganic Chemistry, University of Zürich, Winterthurerstraße
190, CH-8057 Zürich, Switzerland
| |
Collapse
|
20
|
Carroll V, Demoin DW, Hoffman TJ, Jurisson SS. Inorganic chemistry in nuclear imaging and radiotherapy: current and future directions. RADIOCHIM ACTA 2012; 100:653-667. [PMID: 25382874 PMCID: PMC4221859 DOI: 10.1524/ract.2012.1964] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Radiometals play an important role in diagnostic and therapeutic radiopharmaceuticals. This field of radiochemistry is multidisciplinary, involving radiometal production, separation of the radiometal from its target, chelate design for complexing the radiometal in a biologically stable environment, specific targeting of the radiometal to its in vivo site, and nuclear imaging and/or radiotherapy applications of the resultant radiopharmaceutical. The critical importance of inorganic chemistry in the design and application of radiometal-containing imaging and therapy agents is described from a historical perspective to future directions.
Collapse
Affiliation(s)
| | | | - Timothy J Hoffman
- Chemistry, University of Missouri, Columbia, MO 65211, USA
- Internal Medicine, University of Missouri, Columbia, MO 65211, USA
- Harry S Truman Memorial Veterans Hospital, Columbia, MO 65211, USA
| | | |
Collapse
|
21
|
Simms RW, Causey PW, Weaver DM, Sundararajan C, Stephenson KA, Valliant JF. Preparation of technetium-99m bifunctional chelate complexes using a microfluidic reactor: a comparative study with conventional and microwave labeling methods. J Labelled Comp Radiopharm 2011. [DOI: 10.1002/jlcr.1946] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Ryan W. Simms
- Centre for Probe Development and Commercialization, Burke Science Building; McMaster University; Room B231, 1280 Main Street West; Hamilton; ON; Canada; L8S 4K1
| | - Patrick W. Causey
- Centre for Probe Development and Commercialization, Burke Science Building; McMaster University; Room B231, 1280 Main Street West; Hamilton; ON; Canada; L8S 4K1
| | - Darren M. Weaver
- Centre for Probe Development and Commercialization, Burke Science Building; McMaster University; Room B231, 1280 Main Street West; Hamilton; ON; Canada; L8S 4K1
| | - Chitra Sundararajan
- Department of Chemistry; McMaster University; 1280 Main Street West; Hamilton; ON; Canada; L8S 4L8
| | - Karin A. Stephenson
- Centre for Probe Development and Commercialization, Burke Science Building; McMaster University; Room B231, 1280 Main Street West; Hamilton; ON; Canada; L8S 4K1
| | | |
Collapse
|
22
|
Núñez-Montenegro A, Carballo R, Hermida-Ramón JM, Vázquez-López EM. Synthesis, characterization, reactivity and computational studies of new rhenium(I) complexes with thiosemicarbazone ligands derived from 4-(methylthio)benzaldehyde. Polyhedron 2011. [DOI: 10.1016/j.poly.2011.05.033] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
23
|
Lattuada L, Barge A, Cravotto G, Giovenzana GB, Tei L. The synthesis and application of polyamino polycarboxylic bifunctional chelating agents. Chem Soc Rev 2011; 40:3019-49. [DOI: 10.1039/c0cs00199f] [Citation(s) in RCA: 139] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
24
|
Abstract
The chemical modification of oligomers such as DNA, PNA, MORF, LNA to attach radionuclides for nuclear imaging and radiotherapy applications has become a field rich in innovation as older methods are improved and new methods are introduced. This review intends to provide a brief overview of several chelators currently in use for the labeling of oligomers with metallic radionuclides such as 99mTc, 111In and 188Re. While DNA and its analogs have been radiolabeled with important radionuclides of nonmetals such as 32P, 35S, 14C, 18F and 125I, the labeling methods for these isotopes involve covalent chemistry that is quite distinct from the coordinate-covalent chelation chemistry described herein. In this review, we provide a summary of the several chelators that have been covalently conjugated to oligomers for the purpose of radiolabeling with metallic radionuclides by chelation and including details on the conjugation, the choice of radionuclides and labeling methods.
Collapse
Affiliation(s)
| | - Guozheng Liu
- Author to whom correspondence should be addressed; E-Mail: ; Tel: +1-508-856-1958; Fax: +1-508-856-6363
| | | |
Collapse
|
25
|
Das B, Sarkar S, Zangrando E, Chattopadhyay P. Binary and ternary oxorhenium(V) complexes: synthesis, characterization, and crystal structure. J COORD CHEM 2010. [DOI: 10.1080/00958971003649708] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- Biswajit Das
- a Department of Chemistry , Burdwan University , Golapbag, Burdwan 713104, India
| | - Sandipan Sarkar
- a Department of Chemistry , Burdwan University , Golapbag, Burdwan 713104, India
| | - Ennio Zangrando
- b Dipartimento di Scienze Chimiche , Via Licio Giorgieri 1 , 34127 Trieste, Italy
| | | |
Collapse
|
26
|
Nguyen HH, Abram U. Rhenium and technetium complexes with tridentate S,N,O ligands derived from benzoylhydrazine. Polyhedron 2009. [DOI: 10.1016/j.poly.2009.09.012] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
27
|
Synthesis and structural characterization of novel neutral fac-M(CO)3(NSO) complexes (M=Re, 99mTc) with N-acetylcysteine derivatives as tridentate NSO ligands. Polyhedron 2009. [DOI: 10.1016/j.poly.2009.05.010] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
28
|
Kothari KK, Pillarsetty NK, Katti KV, Volkert W. Characterization of complexation reactions of mono- and bidentate-hydroxymethyl phosphine ligands with the organometallic 99mTc(I)(OH2)3(CO)3
+ synthon. RADIOCHIM ACTA 2009. [DOI: 10.1524/ract.91.1.53.19013] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Summary
The complexation reactions of the 99mTc(I)-(CO)3(OH2)3
+ precursor with tris-hydroxymethylenephosphine (THP) and a diphosphine ligand analogue (HMPE) were studied at tracer levels. Results demonstrate rapid formation of 99mTc(I)(CO)3
+ complexes with both THP and HMPE. In the presence of excess THP, conversion of initial complexes to stable, well-defined 99mTc species occurs indicating coordination of phosphine groups to Tc(I) at all three sites trans to the carbonyl ligands.
Collapse
|
29
|
Koumarianou E, Mikołajczak R, Pawlak D, Zikos X, Bouziotis P, Garnuszek P, Karczmarczyk U, Maurin M, Archimandritis SC. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation. Nucl Med Biol 2009; 36:591-603. [DOI: 10.1016/j.nucmedbio.2009.03.006] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2008] [Revised: 02/26/2009] [Accepted: 03/24/2009] [Indexed: 10/20/2022]
|
30
|
Huy Nguyen H, Deflon VM, Abram U. Mixed-Ligand Complexes of Technetium and Rhenium with Tridentate Benzamidines and Bidentate Benzoylthioureas. Eur J Inorg Chem 2009. [DOI: 10.1002/ejic.200900288] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
31
|
Tolmachev V, Wållberg H, Andersson K, Wennborg A, Lundqvist H, Orlova A. The influence of Bz-DOTA and CHX-A″-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for 114mIn-mediated targeting therapy. Eur J Nucl Med Mol Imaging 2009; 36:1460-8. [DOI: 10.1007/s00259-009-1134-9] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2008] [Accepted: 03/23/2009] [Indexed: 10/20/2022]
|
32
|
Deutscher SL, Figueroa SD, Kumar SR. Tumor targeting and SPECT imaging properties of an (111)In-labeled galectin-3 binding peptide in prostate carcinoma. Nucl Med Biol 2009; 36:137-46. [PMID: 19217525 DOI: 10.1016/j.nucmedbio.2008.10.015] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2008] [Revised: 10/15/2008] [Accepted: 10/27/2008] [Indexed: 10/21/2022]
Abstract
INTRODUCTION Galectin-3 (gal-3) is a carbohydrate binding protein that has been implicated in cell adhesion, tumor invasion and metastasis. The objective of this study was to evaluate the tumor targeting and imaging properties of a gal-3 binding peptide selected by phage display in a mouse model of metastatic human prostate carcinoma expressing gal-3. METHODS A gal-3 binding peptide, ANTPCGPYTHDCPVKR, was synthesized with a Gly-Ser-Gly (GSG) spacer and 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA) and then radiolabeled with (111)In. The in vitro cell binding properties of (111)In-DOTA-(GSG)-ANTPCGPYTHDCPVKR were determined in metastatic human PC3-M prostate carcinoma cells. The pharmacokinetics and single-photon emission computed tomographic (SPECT/CT) imaging with the radiolabeled peptide were evaluated in SCID mice bearing human PC3-M prostate carcinoma tumor xenografts. RESULTS The radiolabeled peptide bound with a 50% inhibitory concentration of 191+/-10.2 nM to cultured PC3-M prostate carcinoma cells. In vivo tumor uptake and retention coupled with fast whole-body clearance of the peptide were demonstrated in PC3-M tumor-bearing SCID mice. The tumor uptake rates of the radiolabeled peptide were 1.27+/-0.10%ID/g at 30 min, 0.82+/-0.15%ID/g at 1 h and 0.57+/-0.09%ID/g at 2 h. MicroSPECT/CT studies revealed good tumor uptake of (111)In-DOTA-(GSG)-ANTPCGPYTHDCPVKR 2 h postinjection, while uptake in normal organs was low, with the exception of the kidneys. CONCLUSIONS In vitro cell binding along with tumor uptake of (111)In-DOTA-(GSG)-ANTPCGPYTHDCPVKR in PC3-M human prostate carcinoma tumor-bearing SCID mice suggests the potential of this peptide as a radiopharmaceutical for imaging of gal-3-expressing prostate tumors.
Collapse
Affiliation(s)
- Susan L Deutscher
- Department of Biochemistry, University of Missouri-Columbia School of Medicine, Columbia, MO 65211, USA
| | | | | |
Collapse
|
33
|
Wei L, Zhang X, Gallazzi F, Miao Y, Jin X, Brechbiel MW, Xu H, Clifford T, Welch MJ, Lewis JS, Quinn TP. Melanoma imaging using (111)In-, (86)Y- and (68)Ga-labeled CHX-A''-Re(Arg11)CCMSH. Nucl Med Biol 2009; 36:345-54. [PMID: 19423001 DOI: 10.1016/j.nucmedbio.2009.01.007] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2008] [Revised: 12/15/2008] [Accepted: 01/05/2009] [Indexed: 11/18/2022]
Abstract
INTRODUCTION A novel alpha-melanocyte-stimulating hormone peptide analog CHX-A''-Re(Arg(11))CCMSH, which targeted the melanocortin-1 receptor (MC1-R) overexpressed on melanoma cells, was investigated for its biodistribution and tumor imaging properties. METHODS The metal bifunctional chelator CHX-A'' was conjugated to the melanoma targeting peptide (Arg(11))CCMSH and cyclized by Re incorporation to yield CHX-A''-Re(Arg(11))CCMSH. CHX-A''-Re(Arg(11))CCMSH was labeled with (111)In, (86)Y and (68)Ga, and the radiolabeled peptides were examined in B16/F1 melanoma-bearing mice for their pharmacokinetic as well as their tumor targeting properties using small animal SPECT and PET. RESULTS The radiolabeling efficiencies of the (111)In-, (86)Y- and (68)Ga-labeled CHX-A''-Re(Arg(11))CCMSH peptides were >95%, resulting in specific activities of 4.44, 3.7 and 1.85 MBq/microg, respectively. Tumor uptake of the (111)In-, (86)Y- and (68)Ga-labeled peptides was rapid with 4.17+/-0.94, 4.68+/-1.02 and 2.68+/-0.69 %ID/g present in the tumors 2 h postinjection, respectively. Disappearance of radioactivity from the normal organs and tissues was rapid with the exception of the kidneys. Melanoma tumors were imaged with all three radiolabeled peptides 2 h postinjection. MC1-R-specific uptake was confirmed by competitive receptor blocking studies. CONCLUSIONS Melanoma tumor uptake and imaging was exhibited by the (111)In-, (86)Y- and (68)Ga-labeled Re(Arg(11))CCMSH peptides, although the tumor uptake was moderated by low specific activity. The facile radiolabeling properties of CHX-A''-Re(Arg(11))CCMSH allow it to be employed as a melanoma imaging agent with little or no purification after (111)In, (86)Y and (68)Ga labeling.
Collapse
Affiliation(s)
- Lihui Wei
- Department of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Gottschaldt M, Schubert US. Prospects of metal complexes peripherally substituted with sugars in biomedicinal applications. Chemistry 2009; 15:1548-57. [PMID: 19130511 DOI: 10.1002/chem.200802013] [Citation(s) in RCA: 72] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Metal complexes possess unique tunable properties, such as radioactivity, cytotoxicity or photophysical features, enabling them to act as diagnostic tracers or therapeutic agents. In applying them in biological systems, it is often necessary to enhance their solubility and biocompatibility. To achieve such goals, like the targeting of binding domains, transport systems and enzyme activities, the attachment of carbohydrate moieties appears to be suitable. Sugar-substitution in the periphery of metal complexes has therefore become a strongly growing field of research. Outlined herein is a selection of recent examples.
Collapse
Affiliation(s)
- Michael Gottschaldt
- Laboratory for Organic and Macromolecular Chemistry, Friedrich-Schiller-University Jena, Humboldtstrasse 10, 07743 Jena, Germany.
| | | |
Collapse
|
35
|
Aqueous syntheses of [(Cp-R)M(CO)3] type complexes (Cp=cyclopentadienyl, M=Mn, 99mTc, Re) with bioactive functionalities. J Organomet Chem 2009. [DOI: 10.1016/j.jorganchem.2008.12.006] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
36
|
|
37
|
Miao Y, Quinn TP. Peptide-targeted radionuclide therapy for melanoma. Crit Rev Oncol Hematol 2008; 67:213-28. [PMID: 18387816 PMCID: PMC3197246 DOI: 10.1016/j.critrevonc.2008.02.006] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2007] [Revised: 02/06/2008] [Accepted: 02/20/2008] [Indexed: 12/23/2022] Open
Abstract
Melanocortin-1 receptor (MC1-R) and melanin are two attractive melanoma-specific targets for peptide-targeted radionuclide therapy for melanoma. Radiolabeled peptides targeting MC1-R/melanin can selectively and specifically target cytotoxic radiation generated from therapeutic radionuclides to melanoma cells for cell killing, while sparing the normal tissues and organs. This review highlights the recent advances of peptide-targeted radionuclide therapy of melanoma targeting MC1-R and melanin. The promising therapeutic efficacies of 188Re-(Arg(11))CCMSH (188Re-[Cys(3,4,10), D-Phe(7),Arg(11)]-alpha-MSH(3-13)), 177Lu- and 212Pb-labeled DOTA-Re(Arg(11))CCMSH (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-[ReO-(Cys(3,4,10), D-Phe(7), Arg(11))]-alpha-MSH(3-13)) and 188Re-HYNIC-4B4 (188Re-hydrazinonicotinamide-Tyr-Glu-Arg-Lys-Phe-Trp-His-Gly-Arg-His) in preclinical melanoma-bearing models demonstrate an optimistic outlook for peptide-targeted radionuclide therapy for melanoma. Peptide-targeted radionuclide therapy for melanoma will likely contribute in an adjuvant setting, once the primary tumor has been surgically removed, to treat metastatic deposits and for treatment of end-stage disease. The lack of effective treatments for metastatic melanoma and end-stage disease underscores the necessity to develop and implement new treatment strategies, such as peptide-targeted radionuclide therapy.
Collapse
Affiliation(s)
- Yubin Miao
- College of Pharmacy, University of New Mexico, Albuquerque, NM 87131, USA
- Cancer Research and Treatment Center, University of New Mexico, Albuquerque, NM 87131, USA
- Department of Dermatology, University of New Mexico, Albuquerque, NM 87131, USA
| | - Thomas P. Quinn
- Department of Biochemistry, University of Missouri, Columbia, MO 65211, USA
- Department of Radiology, University of Missouri, Columbia, MO 65211, USA
- Harry S. Truman Memorial Veteran Hospital, Columbia, MO 65201, USA
| |
Collapse
|
38
|
Liu S. Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv Drug Deliv Rev 2008; 60:1347-70. [PMID: 18538888 PMCID: PMC2539110 DOI: 10.1016/j.addr.2008.04.006] [Citation(s) in RCA: 299] [Impact Index Per Article: 18.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2007] [Accepted: 04/16/2008] [Indexed: 11/23/2022]
Abstract
Receptor-based radiopharmaceuticals are of great current interest in molecular imaging and radiotherapy of cancers, and provide a unique tool for target-specific delivery of radionuclides to the diseased tissues. In general, a target-specific radiopharmaceutical can be divided into four parts: targeting biomolecule (BM), pharmacokinetic modifying (PKM) linker, bifunctional coupling or chelating agent (BFC), and radionuclide. The targeting biomolecule serves as a "carrier" for specific delivery of the radionuclide. PKM linkers are used to modify radiotracer excretion kinetics. BFC is needed for radiolabeling of biomolecules with a metallic radionuclide. Different radiometals have significant difference in their coordination chemistry, and require BFCs with different donor atoms and chelator frameworks. Since the radiometal chelate can have a significant impact on physical and biological properties of the target-specific radiopharmaceutical, its excretion kinetics can be altered by modifying the coordination environment with various chelators or coligand, if needed. This review will focus on the design of BFCs and their coordination chemistry with technetium, copper, gallium, indium, yttrium and lanthanide radiometals.
Collapse
Affiliation(s)
- Shuang Liu
- School of Health Sciences, Purdue University, West Lafayette, USA.
| |
Collapse
|
39
|
Das B, Sarkar S, Patra A, Drew MGB, Chattopadhyay P. Trichloro-mono- β -diketonato oxorhenium(V) complexes: synthesis, characterization and crystal structure. J COORD CHEM 2008. [DOI: 10.1080/00958970701764678] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- Biswajit Das
- a Department of Chemistry , The University of Burdwan , Golapbag, Burdwan - 713104, India
| | - Sandipan Sarkar
- a Department of Chemistry , The University of Burdwan , Golapbag, Burdwan - 713104, India
| | - Animesh Patra
- a Department of Chemistry , The University of Burdwan , Golapbag, Burdwan - 713104, India
| | - Michael G. B. Drew
- b Department of Chemistry , Reading University , Reading RG6 6AD, Berks, England
| | - Pabitra Chattopadhyay
- a Department of Chemistry , The University of Burdwan , Golapbag, Burdwan - 713104, India
| |
Collapse
|
40
|
Marchi A, Marchesi E, Marvelli L, Bergamini P, Bertolasi V, Ferretti V. New Water-Soluble Rhenium Complexes with 1,3,5-Triaza-7-phosphaadamantane (PTA) – X-ray Crystal Structures of [ReNCl2(PTA)3], [ReO2Cl(PTA)3], [ReCl3(PTA)2(PPh3)], and [Re2N2Cl3(Et2dtc)(PTA)4]. Eur J Inorg Chem 2008. [DOI: 10.1002/ejic.200800114] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
41
|
Chowdhury S, Nogami M, Canlier A, Koshino N, Ikeda Y. Molecular structures and redox properties of oxorhenium(V) ‘3+1’ mixed ligand complexes with heterocyclic thiolates containing nitrogen. Inorganica Chim Acta 2008. [DOI: 10.1016/j.ica.2007.09.011] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
42
|
Chiotellis A, Tsoukalas C, Pelecanou M, Raptopoulou C, Terzis A, Papadopoulos M, Papadopoulou-Daifoti Z, Pirmettis I. Convenient Route Leading to Neutral fac-M(CO)3(NNO) Complexes (M = Re, 99mTc) Coupled to Amine Pharmacophores. Inorg Chem 2008; 47:2601-7. [DOI: 10.1021/ic7019268] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Aris Chiotellis
- Institute of Radioisotopes−Radiodiagnostic Products, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Biology, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Materials Science, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Department of Pharmacology, Medical School, University of Athens, 11527 Athens, Greece
| | - Charalambos Tsoukalas
- Institute of Radioisotopes−Radiodiagnostic Products, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Biology, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Materials Science, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Department of Pharmacology, Medical School, University of Athens, 11527 Athens, Greece
| | - Maria Pelecanou
- Institute of Radioisotopes−Radiodiagnostic Products, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Biology, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Materials Science, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Department of Pharmacology, Medical School, University of Athens, 11527 Athens, Greece
| | - Catherine Raptopoulou
- Institute of Radioisotopes−Radiodiagnostic Products, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Biology, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Materials Science, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Department of Pharmacology, Medical School, University of Athens, 11527 Athens, Greece
| | - Aris Terzis
- Institute of Radioisotopes−Radiodiagnostic Products, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Biology, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Materials Science, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Department of Pharmacology, Medical School, University of Athens, 11527 Athens, Greece
| | - Minas Papadopoulos
- Institute of Radioisotopes−Radiodiagnostic Products, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Biology, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Materials Science, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Department of Pharmacology, Medical School, University of Athens, 11527 Athens, Greece
| | - Zetta Papadopoulou-Daifoti
- Institute of Radioisotopes−Radiodiagnostic Products, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Biology, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Materials Science, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Department of Pharmacology, Medical School, University of Athens, 11527 Athens, Greece
| | - Ioannis Pirmettis
- Institute of Radioisotopes−Radiodiagnostic Products, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Biology, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Institute of Materials Science, National Centre for Scientific Research “Demokritos”, 15310 Athens, Greece, Department of Pharmacology, Medical School, University of Athens, 11527 Athens, Greece
| |
Collapse
|
43
|
Tanaka K, Fukase K. PET (positron emission tomography) imaging of biomolecules using metal-DOTA complexes: a new collaborative challenge by chemists, biologists, and physicians for future diagnostics and exploration of in vivo dynamics. Org Biomol Chem 2008; 6:815-28. [PMID: 18292870 DOI: 10.1039/b718157b] [Citation(s) in RCA: 104] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
Recently, PET has been paid a great deal of attention as a non-invasive imaging method. In this review, the recent advances of PET using biomolecules, such as peptides, monoclonal antibodies, proteins, oligonucleotides, and glycoproteins will be described. So far, PET of biomolecules has been mainly used for diagnosis of cancers. The biomolecules have been conjugated with the DOTA ligand, labeled with radiometals as the beta+ emitter, and targeted to specific tumors, where they have enabled visualization of even small metastatic lesions, due to the high sensitivity of the PET scanners. Some of the biomolecules have been used not only for PET diagnosis, but also for radiotherapeutic treatments by simply changing the radiometals to beta(-) emitters. Collaborative work between chemists, biologists, and physicians will be important for the future of biomolecule-based targeting and diagnosis.
Collapse
Affiliation(s)
- Katsunori Tanaka
- Department of Chemistry, Graduate School of Science, Osaka University, Machikaneyama 1-1, Toyonaka, Osaka 560-0043, Japan.
| | | |
Collapse
|
44
|
Paganelli G, Ferrari M, Ravasi L, Cremonesi M, De Cicco C, Galimberti V, Sivolapenko G, Luini A, De Santis R, Travaini LL, Fiorenza M, Chinol M, Papi S, Zanna C, Carminati P, Veronesi U. Intraoperative avidination for radionuclide therapy: a prospective new development to accelerate radiotherapy in breast cancer. Clin Cancer Res 2007; 13:5646s-5651s. [PMID: 17875802 DOI: 10.1158/1078-0432.ccr-07-1058] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE In a continuous effort to seek for anticancer treatments with minimal side effects, we aim at proving the feasibility of the Intraoperative Avidination for Radionuclide Therapy, a new procedure for partial breast irradiation. EXPERIMENTAL DESIGN To assess doses of 90Y-DOTA-biotin to target (i.e., breast tumor bed) and nontarget organs, we did simulation studies with 111In-DOTA-biotin in 10 candidates for conservative breast surgery. Immediately after quadrantectomy, patients were injected with 100-mg avidin in the tumor bed. On the following day, patients were given 111In-DOTA-biotin (approximately 111 MBq) i.v. after appropriate chase of biotinylated albumin (20 mg) to remove circulating avidin. Biokinetic studies were done by measuring radioactivity in scheduled blood samples, 48-h urine collection, and through scintigraphic images. The medical internal radiation dose formalism (OLINDA code) enabled dosimetry assessment in target and nontarget organs. RESULTS Images showed early and long-lasting radioactive biotin uptake in the operated breast. Rapid blood clearance (<1% at 12 h) and urine excretion (>75% at 24 h) were observed. Absorbed doses, expressed as mean+/-SD in Gy/GBq, were as low as 0.15+/-0.05 in lungs, 0.10+/-0.02 in heart, 0.06+/-0.02 in red marrow, 1.30+/-0.50 in kidneys, 1.50+/-0.30 in urinary bladder, and 0.06+/-0.02 in total body, whereas in the targeted area, they increased to 5.5+/-1.1 Gy/GBq (50% ISOROI) and 4.8+/-1.0 Gy/GBq (30% ISOROI). CONCLUSION Our preliminary results suggest that Intraoperative Avidination for Radionuclide Therapy is a simple and feasible procedure that may improve breast cancer patients' postsurgical management by shortening radiotherapy duration.
Collapse
Affiliation(s)
- Giovanni Paganelli
- Division of Nuclear Medicine, European Institute of Oncology, Milan, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Klausmeyer KK, Beckles FR. Synthesis and characterization of binuclear rhenium(I) complexes containing bifunctional ligands. Inorganica Chim Acta 2007. [DOI: 10.1016/j.ica.2007.03.034] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
46
|
Alberto R, Angst D, Ortner K, Abram U, Schubiger PA, Kaden TA. Syntheses of a series of S6 thioether cages and their coordination chemistry with Ag+. NEW J CHEM 2007. [DOI: 10.1039/b606510b] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
47
|
Paganelli G, Ferrari M, Cremonesi M, De Cicco C, Galimberti V, Luini A, Veronesi P, Fiorenza M, Carminati P, Zanna C, Orecchia R, Veronesi U. IART: intraoperative avidination for radionuclide treatment. A new way of partial breast irradiation. Breast 2006; 16:17-26. [PMID: 17174093 DOI: 10.1016/j.breast.2006.10.003] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2006] [Revised: 09/19/2006] [Accepted: 10/04/2006] [Indexed: 11/25/2022] Open
Abstract
A new procedure, known as Intraoperative Avidination for Radionuclide Therapy (IART), is described in breast cancer patients. In this paper, we provide proof of the principle that intraoperative injection of avidin in the tumour bed after quadrantectomy allows homing in of intravenously (IV) administered radioactive biotin to the target site. This approach of targeted therapy consists of two steps: (i) "avidination" of the anatomical area of the tumour with avidin injected by the surgeon, into and around the tumour bed; (ii) targeting the anatomical area of the tumour by IV injection of radiolabelled biotin. The scintigraphic images demonstrated fast and stable uptake of labelled biotin at the site of operated breast. The radiation dose released to the index quadrant was more than 5 Gy/GBq, consistent with a boost of 20 Gy for an activity of 3.7 GBq 90Y-biotin (100mCi). A further large clinical trial facing IART in combination with reduced external-beam radiotherapy is, in our opinion, fully justified.
Collapse
Affiliation(s)
- Giovanni Paganelli
- Division of Nuclear Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Gottschaldt M, Pfeifer A, Koth D, Görls H, Dahse HM, Möllmann U, Obata M, Yano S. Silver(I) complexes based on novel tripodal thioglycosides: synthesis, structure and antimicrobial activity. Tetrahedron 2006. [DOI: 10.1016/j.tet.2006.09.038] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
49
|
Abstract
Radiolabelled peptides are used for specific targeting of receptors (over-)expressed by tumour cells. Dependent on the kind of labelling and the radionuclide used, these compounds may be utilised for imaging or for therapy. A concise overview is provided on basic principles of designing and developing radiopeptides for these applications. Furthermore, clinical application of these compounds for imaging and therapy is described. Advantages of the method compared to other techniques (such as the use of radiolabelled antibodies or antibody fragments) are discussed as well as pitfalls and limitations.
Collapse
Affiliation(s)
- Martin Gotthardt
- Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
| | | | | | | |
Collapse
|
50
|
Tzanopoulou S, Pirmettis IC, Patsis G, Paravatou-Petsotas M, Livaniou E, Papadopoulos M, Pelecanou M. Synthesis, Characterization, and Biological Evaluation of M(I)(CO)3(NNO) Complexes (M = Re, 99mTc) Conjugated to 2-(4-Aminophenyl)benzothiazole as Potential Breast Cancer Radiopharmaceuticals. J Med Chem 2006; 49:5408-10. [PMID: 16942013 DOI: 10.1021/jm0606387] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The synthesis and biological evaluation of new M(I)(CO)3(NNO) (M = Re, 99mTc) complexes attached to the antitumor agent 2-(4-aminophenyl)benzothiazole are reported. The fluorescent rhenium complex enters MCF-7 breast cancer cells but does not enter normal HFFF-2 and MRC-5 cells. The analogous radioactive 99mTc complex produces fast blood and soft tissue clearance when administered to healthy mice. These complexes are promising candidates for developing radiopharmaceuticals for imaging (99mTc) and targeted radiotherapy (186Re, 188Re) of breast cancer.
Collapse
Affiliation(s)
- Stamatia Tzanopoulou
- Institute of Biology, National Centre for Scientific Research Demokritos, 15310 Athens, Greece
| | | | | | | | | | | | | |
Collapse
|